Impact Factor
3.29
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.17
632 total citations
h5-index
27
h5 depth signal
Cited share
75.5%
231 of 306
Total citations
632
Citation footprint
Metric signal
2.19
External metric anchor
Self-citation
2.5%
16 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
425
Sweden
353
Denmark
246
Norway
188
Japan
149
Citing Fields of Research
Digestive Disorders
1,058
Inflammatory Bowel Diseases & Infections
517
Liver Diseases
431
Liver & Colon Cancer
319
Hepatitis
225
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
13,773
Articles tracked across the journal lifetime
Indexed publication set
306
231 cited publications
Last 12 months
158
13.2 publications/month
Open access share
35.4%
56 OA publications in the last year
Leading citing country
China
425 citing publications
Leading citing field
Digestive Disorders
1,058 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1966-
v1n1, 1966-
Active Coverage
Research Focus & Classification
Indexed Subjects
Digestive Disorders
Inflammatory Bowel Diseases & Infections
Liver Diseases
Liver & Colon Cancer
Broad Categories
Gastroenterology
Digestive Disorders
Inflammatory Bowel Diseases & Infections
Liver & Colon Cancer
Hepatitis
MeSH Descriptors
Gastroenterology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1080/00365521.2026.2748834
Open DOI
Inter-α-inhibitor heavy chain 4 levels in incident and prevalent patients with primary biliary cholangitis
03
DOI 10.1080/00365521.2026.2745974
Open DOI
Defining and measuring disease burden in Crohn’s disease: a systematic literature review
Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease characterised by heterogeneous clinical manifestations and a lifelong disease course. As therapeutic strategies have evolved ...
04
DOI 10.1080/00365521.2026.2745977
Open DOI
Physical activity in individuals with inflammatory bowel disease: a Danish population-based repeated cross-sectional study
05
DOI 10.1080/00365521.2026.2745981
Open DOI
Aortoduodenal syndrome: evolving management of a rare cause of duodenal obstruction in the endovascular era
06
07
DOI 10.1080/00365521.2026.2745983
Open DOI
P-CAB − amoxicillin dual therapy for H. pylori eradication: a narrative review of efficacy, safety, and guideline positioning
Helicobacter pylori (H. pylori) infection remains one of the most prevalent bacterial infections, and affects approximately half of the global population. The infection is the principal etiologic a...
08
DOI 10.1080/00365521.2026.2745986
Open DOI
Optimizing management strategies for T4b esophageal cancer: the role of TEVAR in multimodal treatment approaches
09
DOI 10.1080/00365521.2026.2742236
Open DOI
Histological characteristics of the lower esophagus among persons with and without GERD in a general population
Gastroesophageal reflux disease (GERD) is one of our most common global health problems [1,2]. Globally, the estimated age-standardized prevalence of GERD, defined as heartburn and/or regurgitation...
10
DOI 10.1080/00365521.2026.2742242
Open DOI
Endoscopic radiofrequency ablation for unresectable cholangiocarcinoma: a single-centre retrospective cohort study with patient interviews
Cholangiocarcinoma (CCA) is a rare bile duct malignancy, accounting for 3% of gastrointestinal malignancies worldwide and 250 new cases in Norway annually [1,2]. Many patients present with advanced...
Bibliographical & Catalog Notes
Also issued online.